Horizon Discovery’s SMARTvector shRNA Technology Deployed in Celyad’s Successful IND Filing for Next-Generation CAR-T Cel...
08 July 2019 - 5:33PM
Business Wire
- Phase 1 trial scheduled for early 2020 will be first CAR-T cell
therapy clinical trial to employ SMARTvector technology
- Horizon will receive a milestone payment for the successful IND
filing of CYAD-02, autologous NKG2D-based CAR-T candidate
Horizon Discovery Group plc (LSE: HZD) (“Horizon”), a company
driving the application of gene editing and gene modulation within
the global life science market, today announced that Celyad
(Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage
biopharmaceutical company focused on the development of CAR-T
cell-based therapies, received FDA Acceptance of Investigational
New Drug (IND) application for the autologous NKG2D based CAR-T
cell therapy CYAD-02 that deploys Horizon’s optimized SMARTvector™
shRNA technology. The Phase 1 trial will be the first CAR-T cell
therapy to employ the SMARTvector platform. Horizon will receive an
undisclosed milestone payment for the successful IND filing.
Celyad has been investigating the use of shRNAs to support the
clinical development of its CAR-T cell platform. The FDA approved
IND application involves CYAD-02, a next generation CAR-T cell
therapy in which shRNA is employed to suppress two genes. Celyad
has pre-clinical data indicating that this improves in vivo
engraftment and efficacy of CYAD-02.
A Phase 1 dose-escalation trial evaluating the safety and
clinical activity of CYAD-02 is planned for early 2020 and will
involve a preconditioning chemotherapy (CyFlu) in patients with
relapse/refractory (r/r) acute myeloid leukemia (AML) or
myelodysplastic syndromes (MDS).
Terry Pizzie, Chief Executive Officer, Horizon Discovery
Group plc, commented: “We see great potential for shRNA
technology in the optimization of next-generation cell therapies.
The success of this IND filing is testament to the strength of our
relationship with Celyad, and the powerful combination of Horizon’s
SMARTvector shRNA platform with Celyad’s CAR-T expertise.”
Filippo Petti, Chief Executive Officer, Celyad, said:
“Over the past few years Celyad has made great strides in
evaluating our NKG2D-based CAR-T therapy for the treatment of
relapsed/refractory acute myeloid leukemia and myelodysplastic
syndrome. The FDA approval for the CYAD-02 IND application will
allow us to evaluate new therapies in this difficult to treat
population and the inclusion of an optimized shRNA developed using
Horizon’s SMARTvector technology represents the output of a strong
collaboration. We look forward to a continued successful
relationship.”
ENDS
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190708005251/en/
Katie Odgaard Tel: +44 (0)7787 502 947 Email:
katie.odgaard@zymecommunications.com
Horizon Discovery (LSE:HZD)
Historical Stock Chart
From Apr 2024 to May 2024
Horizon Discovery (LSE:HZD)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Horizon Discovery Group Plc (London Stock Exchange): 0 recent articles
More Horizon Discvry News Articles